FI104496B - Yliekspressiojärjestelmät kolera B-alayksikön ekspressiota varten vieraiden promoottoreiden ja johtopeptidien avulla - Google Patents

Yliekspressiojärjestelmät kolera B-alayksikön ekspressiota varten vieraiden promoottoreiden ja johtopeptidien avulla Download PDF

Info

Publication number: FI104496B
Authority: FI; Finland
Prior art keywords: ctb; protein; gene; promoter; coli
Prior art date: 1988-09-16

Application number

FI894368A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI894368A (fi

FI894368A0 (fi

Inventor

Jan Holmgren

Castillo Joaquin Sanches

Original Assignee

Vitec Aktiebolag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-09-16

Filing date

1989-09-15

Publication date

2000-02-15

1989-09-15 Application filed by Vitec Aktiebolag filed Critical Vitec Aktiebolag

1989-09-15 Publication of FI894368A0 publication Critical patent/FI894368A0/fi

1990-03-17 Publication of FI894368A publication Critical patent/FI894368A/fi

2000-02-15 Application granted granted Critical

2000-02-15 Publication of FI104496B publication Critical patent/FI104496B/fi

Links

230000014509 gene expression Effects 0.000 title claims abstract description 28
108010076504 Protein Sorting Signals Proteins 0.000 title claims abstract description 15
230000002018 overexpression Effects 0.000 title claims description 19
206010008631 Cholera Diseases 0.000 title description 10
108090000623 proteins and genes Proteins 0.000 claims abstract description 89
102000004169 proteins and genes Human genes 0.000 claims abstract description 58
108010049048 Cholera Toxin Proteins 0.000 claims abstract description 53
102000009016 Cholera Toxin Human genes 0.000 claims abstract description 51
230000027455 binding Effects 0.000 claims abstract description 13
108020001507 fusion proteins Proteins 0.000 claims abstract description 10
241000607626 Vibrio cholerae Species 0.000 claims description 36
241000588724 Escherichia coli Species 0.000 claims description 32
101150005152 ctb gene Proteins 0.000 claims description 24
108090000765 processed proteins & peptides Proteins 0.000 claims description 13
239000003053 toxin Substances 0.000 claims description 13
231100000765 toxin Toxicity 0.000 claims description 13
108700012359 toxins Proteins 0.000 claims description 13
238000004519 manufacturing process Methods 0.000 claims description 9
239000000147 enterotoxin Substances 0.000 claims description 8
231100000655 enterotoxin Toxicity 0.000 claims description 8
229940046166 oligodeoxynucleotide Drugs 0.000 claims description 8
239000013600 plasmid vector Substances 0.000 claims description 8
108091034117 Oligonucleotide Proteins 0.000 claims description 7
101710137500 T7 RNA polymerase Proteins 0.000 claims description 7
101710146739 Enterotoxin Proteins 0.000 claims description 6
229940118696 vibrio cholerae Drugs 0.000 claims description 4
230000024033 toxin binding Effects 0.000 claims description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
230000022532 regulation of transcription, DNA-dependent Effects 0.000 claims 2
KPZGRMZPZLOPBS-UHFFFAOYSA-N 1,3-dichloro-2,2-bis(chloromethyl)propane Chemical compound ClCC(CCl)(CCl)CCl KPZGRMZPZLOPBS-UHFFFAOYSA-N 0.000 claims 1
JTEJPPKMYBDEMY-UHFFFAOYSA-N 5-methoxytryptamine Chemical compound COC1=CC=C2NC=C(CCN)C2=C1 JTEJPPKMYBDEMY-UHFFFAOYSA-N 0.000 claims 1
HXNNRBHASOSVPG-GUBZILKMSA-N Ala-Glu-Leu Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O HXNNRBHASOSVPG-GUBZILKMSA-N 0.000 claims 1
DVKQPQKQDHHFTE-ZLUOBGJFSA-N Cys-Cys-Asn Chemical compound C([C@@H](C(=O)O)NC(=O)[C@H](CS)NC(=O)[C@H](CS)N)C(=O)N DVKQPQKQDHHFTE-ZLUOBGJFSA-N 0.000 claims 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
GZAUZBUKDXYPEH-CIUDSAMLSA-N Leu-Cys-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)O)N GZAUZBUKDXYPEH-CIUDSAMLSA-N 0.000 claims 1
YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 claims 1
RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 claims 1
FELJDCNGZFDUNR-WDSKDSINSA-N Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1 FELJDCNGZFDUNR-WDSKDSINSA-N 0.000 claims 1
241000607493 Vibrionaceae Species 0.000 claims 1
241000525018 Vibrionaceae bacterium Species 0.000 claims 1
108010010430 asparagine-proline-alanine Proteins 0.000 claims 1
239000002775 capsule Substances 0.000 claims 1
235000012000 cholesterol Nutrition 0.000 claims 1
101150060022 med gene Proteins 0.000 claims 1
238000000034 method Methods 0.000 abstract description 27
210000000170 cell membrane Anatomy 0.000 abstract description 3
108020004511 Recombinant DNA Proteins 0.000 abstract 1
230000005945 translocation Effects 0.000 abstract 1
239000013612 plasmid Substances 0.000 description 58
235000018102 proteins Nutrition 0.000 description 40
210000004027 cell Anatomy 0.000 description 22
108020004414 DNA Proteins 0.000 description 20
235000001014 amino acid Nutrition 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 19
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 15
239000002609 medium Substances 0.000 description 12
238000002965 ELISA Methods 0.000 description 11
230000001580 bacterial effect Effects 0.000 description 11
230000012010 growth Effects 0.000 description 9
229960000723 ampicillin Drugs 0.000 description 8
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 8
230000004927 fusion Effects 0.000 description 8
230000021615 conjugation Effects 0.000 description 7
239000000203 mixture Substances 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
239000000427 antigen Substances 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
238000002474 experimental method Methods 0.000 description 6
210000002966 serum Anatomy 0.000 description 6
101150021331 toxR gene Proteins 0.000 description 6
238000012546 transfer Methods 0.000 description 6
241000700159 Rattus Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
238000005119 centrifugation Methods 0.000 description 5
239000012228 culture supernatant Substances 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
239000000499 gel Substances 0.000 description 5
230000003053 immunization Effects 0.000 description 5
238000002649 immunization Methods 0.000 description 5
239000002243 precursor Substances 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 5
229960001225 rifampicin Drugs 0.000 description 5
206010012735 Diarrhoea Diseases 0.000 description 4
241001131785 Escherichia coli HB101 Species 0.000 description 4
101150018411 LTB gene Proteins 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
229940088710 antibiotic agent Drugs 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000000903 blocking effect Effects 0.000 description 4
230000000694 effects Effects 0.000 description 4
239000012634 fragment Substances 0.000 description 4
230000006698 induction Effects 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
230000006798 recombination Effects 0.000 description 4
238000005215 recombination Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
238000012360 testing method Methods 0.000 description 4
230000009466 transformation Effects 0.000 description 4
101150114515 CTBS gene Proteins 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
101800000120 Host translation inhibitor nsp1 Proteins 0.000 description 3
101800000517 Leader protein Proteins 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
101800000512 Non-structural protein 1 Proteins 0.000 description 3
108091028043 Nucleic acid sequence Proteins 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
ARKDJZHBBZECNE-LSYRYXEQSA-N beta-D-Gal-(1->3)-beta-D-GalNAc-(1->4)-[alpha-Neu5Ac-(2->3)]-beta-D-Gal-(1->4)-beta-D-Glc-(1<->1')-Sph Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](N)[C@H](O)/C=C/CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 ARKDJZHBBZECNE-LSYRYXEQSA-N 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000011534 incubation Methods 0.000 description 3
229960000318 kanamycin Drugs 0.000 description 3
229930027917 kanamycin Natural products 0.000 description 3
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
229930182823 kanamycin A Natural products 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000008188 pellet Substances 0.000 description 3
229920003023 plastic Polymers 0.000 description 3
238000000746 purification Methods 0.000 description 3
230000001105 regulatory effect Effects 0.000 description 3
230000028327 secretion Effects 0.000 description 3
238000000527 sonication Methods 0.000 description 3
241000024188 Andala Species 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
230000007023 DNA restriction-modification system Effects 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000001147 anti-toxic effect Effects 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
230000008859 change Effects 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960005091 chloramphenicol Drugs 0.000 description 2
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
229960005004 cholera vaccine Drugs 0.000 description 2
230000002759 chromosomal effect Effects 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
238000010367 cloning Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000010968 computed tomography angiography Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
238000012258 culturing Methods 0.000 description 2
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000011161 development Methods 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
QPJBWNIQKHGLAU-IQZHVAEDSA-N ganglioside GM1 Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@H](NC(=O)CCCCCCCCCCCCCCCCC)[C@H](O)\C=C\CCCCCCCCCCCCC)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](CO)O1 QPJBWNIQKHGLAU-IQZHVAEDSA-N 0.000 description 2
229930186900 holotoxin Natural products 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
210000000936 intestine Anatomy 0.000 description 2
238000002955 isolation Methods 0.000 description 2
101150109249 lacI gene Proteins 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
239000000178 monomer Substances 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000002773 nucleotide Substances 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
210000001322 periplasm Anatomy 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
101150116497 sacm1l gene Proteins 0.000 description 2
239000012723 sample buffer Substances 0.000 description 2
230000007017 scission Effects 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
239000000758 substrate Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
OXWVQXZNTJTTEC-UHFFFAOYSA-N 1-chloro-2h-naphthalen-1-ol Chemical compound C1=CC=C2C(O)(Cl)CC=CC2=C1 OXWVQXZNTJTTEC-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N Arginine Chemical compound OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
FWSKZDLWVKONFS-UHFFFAOYSA-K Cl[Rb].Cl[Ca]Cl Chemical compound Cl[Rb].Cl[Ca]Cl FWSKZDLWVKONFS-UHFFFAOYSA-K 0.000 description 1
238000007399 DNA isolation Methods 0.000 description 1
230000007018 DNA scission Effects 0.000 description 1
108010003471 Fetal Proteins Proteins 0.000 description 1
102000004641 Fetal Proteins Human genes 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
101710121697 Heat-stable enterotoxin Proteins 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
101710090149 Lactose operon repressor Proteins 0.000 description 1
102000003960 Ligases Human genes 0.000 description 1
108090000364 Ligases Proteins 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
241001122767 Theaceae Species 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
241000602423 Vibrio cholerae O1 Species 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
238000013019 agitation Methods 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
239000003513 alkali Substances 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
230000006037 cell lysis Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000030570 cellular localization Effects 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
108010026341 choleragen receptor Proteins 0.000 description 1
210000000349 chromosome Anatomy 0.000 description 1
230000001268 conjugating effect Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
101150062186 cta gene Proteins 0.000 description 1
101150028842 ctxA gene Proteins 0.000 description 1
101150087320 ctxB gene Proteins 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
238000012217 deletion Methods 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000005546 dideoxynucleotide Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
101150030491 eltA gene Proteins 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
229960005542 ethidium bromide Drugs 0.000 description 1
210000001723 extracellular space Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
150000004678 hydrides Chemical class 0.000 description 1
229940124452 immunizing agent Drugs 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000008944 intestinal immunity Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
238000007169 ligase reaction Methods 0.000 description 1
ADKOXSOCTOWDOP-UHFFFAOYSA-L magnesium;aluminum;dihydroxide;trihydrate Chemical compound O.O.O.[OH-].[OH-].[Mg+2].[Al] ADKOXSOCTOWDOP-UHFFFAOYSA-L 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000002703 mutagenesis Methods 0.000 description 1
231100000350 mutagenesis Toxicity 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
238000006384 oligomerization reaction Methods 0.000 description 1
229940126578 oral vaccine Drugs 0.000 description 1
230000008520 organization Effects 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
102000013415 peroxidase activity proteins Human genes 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
229920000024 polymyxin B Polymers 0.000 description 1
229960005266 polymyxin b Drugs 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011027 product recovery Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
108091008146 restriction endonucleases Proteins 0.000 description 1
239000000523 sample Substances 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
230000009469 supplementation Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
238000004448 titration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
238000000844 transformation Methods 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
238000011282 treatment Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
230000009452 underexpressoin Effects 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
239000013598 vector Substances 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Soy Sauces And Products Related Thereto (AREA)
Compositions Of Macromolecular Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
Measuring And Recording Apparatus For Diagnosis (AREA)
Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
Exhaust Gas Treatment By Means Of Catalyst (AREA)

FI894368A 1988-09-16 1989-09-15 Yliekspressiojärjestelmät kolera B-alayksikön ekspressiota varten vieraiden promoottoreiden ja johtopeptidien avulla FI104496B (fi)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE8803291A SE462285B (sv)	1988-09-16	1988-09-16	Expression av koleratoxinets bindande subenhet med hjaelp av fraemmande promotor- och/eller ledarpeptidstrukturer
SE8803291		1988-09-16

Publications (3)

Publication Number	Publication Date
FI894368A0 FI894368A0 (fi)	1989-09-15
FI894368A FI894368A (fi)	1990-03-17
FI104496B true FI104496B (fi)	2000-02-15

Family

ID=20373364

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI894368A FI104496B (fi)	1988-09-16	1989-09-15	Yliekspressiojärjestelmät kolera B-alayksikön ekspressiota varten vieraiden promoottoreiden ja johtopeptidien avulla

Country Status (13)

Country	Link
EP (1)	EP0368819B1 (ja)
JP (1)	JP2790333B2 (ja)
AT (1)	ATE161885T1 (ja)
AU (1)	AU633842B2 (ja)
CA (1)	CA1340577C (ja)
DE (1)	DE68928529T2 (ja)
DK (1)	DK175694B1 (ja)
ES (1)	ES2113342T3 (ja)
FI (1)	FI104496B (ja)
GR (1)	GR3025846T3 (ja)
IS (1)	IS1804B (ja)
NO (1)	NO301175B1 (ja)
SE (1)	SE462285B (ja)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109096403A (zh) *	2018-07-04	2018-12-28	浙江工商大学	一种用于蛋白质转导的蛋白质载体及其制备方法和应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0416505A3 (en) *	1989-09-04	1991-10-02	Takeda Chemical Industries, Ltd.	Expression plasmids and use thereof
US5356797A (en) *	1991-11-15	1994-10-18	Board Of Regents, The University Of Texas	Membrane expression of heterologous genes
EP0613500A1 (en) *	1991-11-15	1994-09-07	The Board Of Regents, The University Of Texas System	Membrane expression of heterologous genes
US5932714A (en) *	1995-02-23	1999-08-03	Connaught Laboratories Limited	Expression of gene products from genetically manipulated strains of Bordetella
US5998168A (en) *	1995-06-07	1999-12-07	Connaught Laboratories Limited	Expression of gene products from genetically manipulated strains of bordetella
US6008329A (en) *	1998-03-06	1999-12-28	The United States Of America As Represented By The Secretary Of The Army	Method for purifying cholera toxin
WO2007117339A2 (en) *	2006-01-11	2007-10-18	The United States Of America As Respresented By The Secretary Of The Navy	Adhesin-enterotoxin chimera based immunogenic composition against entertoxigenic escherichia coli
DE102011111688A1 (de) *	2011-08-24	2013-02-28	Bioserv Analytik Und Medizinprodukte Gmbh	Verfahren zur schnellen Isolation bzw. Aufreinigung von rekombinanten Proteinen mit einer (nicht toxischen) Choleratoxin-Domäne

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666837A (en) *	1982-05-24	1987-05-19	Smithkline-Rit	DNA sequences, recombinant DNA molecules and processes for producing the A and B subunits of cholera toxin and preparations containing so-obtained subunit or subunits
US5135862A (en) *	1983-03-04	1992-08-04	University Of Maryland	Method of isolating restriction fragment deletions in vibrio cholerae, products thereof
US4882278A (en) *	1983-04-29	1989-11-21	President And Fellows Of Harvard College	Non-toxinogenic vibrio cholerae mutants
EP0251579A3 (en) *	1986-06-24	1989-03-22	Enterovax Research Pty. Ltd.	Non-antibiotic marker system
HU205372B (en) *	1987-04-29	1992-04-28	Harvard College	Process for producing vaccines against cholera

1988
- 1988-09-16 SE SE8803291A patent/SE462285B/sv not_active IP Right Cessation
1989
- 1989-09-04 IS IS3505A patent/IS1804B/is unknown
- 1989-09-11 EP EP89850295A patent/EP0368819B1/en not_active Expired - Lifetime
- 1989-09-11 DE DE68928529T patent/DE68928529T2/de not_active Expired - Lifetime
- 1989-09-11 ES ES89850295T patent/ES2113342T3/es not_active Expired - Lifetime
- 1989-09-11 AT AT89850295T patent/ATE161885T1/de not_active IP Right Cessation
- 1989-09-14 JP JP1239733A patent/JP2790333B2/ja not_active Expired - Lifetime
- 1989-09-15 DK DK198904569A patent/DK175694B1/da not_active IP Right Cessation
- 1989-09-15 NO NO893702A patent/NO301175B1/no not_active IP Right Cessation
- 1989-09-15 FI FI894368A patent/FI104496B/fi active IP Right Grant
- 1989-09-15 AU AU41349/89A patent/AU633842B2/en not_active Expired
- 1989-09-15 CA CA000611596A patent/CA1340577C/en not_active Expired - Fee Related
1998
- 1998-01-08 GR GR970402939T patent/GR3025846T3/el unknown

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN109096403A (zh) *	2018-07-04	2018-12-28	浙江工商大学	一种用于蛋白质转导的蛋白质载体及其制备方法和应用
CN109096403B (zh) *	2018-07-04	2020-06-30	浙江工商大学	一种用于蛋白质转导的蛋白质载体及其制备方法和应用

Also Published As

Publication number	Publication date
ES2113342T3 (es)	1998-05-01
NO893702L (no)	1990-03-19
ATE161885T1 (de)	1998-01-15
SE462285B (sv)	1990-05-28
GR3025846T3 (en)	1998-04-30
AU633842B2 (en)	1993-02-11
IS1804B (is)	2002-02-26
FI894368A (fi)	1990-03-17
JPH0322997A (ja)	1991-01-31
DK456989A (da)	1990-03-17
FI894368A0 (fi)	1989-09-15
DE68928529D1 (de)	1998-02-12
CA1340577C (en)	1999-06-01
DK175694B1 (da)	2005-01-24
DE68928529T2 (de)	1998-04-16
IS3505A7 (is)	1990-03-17
JP2790333B2 (ja)	1998-08-27
NO301175B1 (no)	1997-09-22
AU4134989A (en)	1990-04-05
SE8803291D0 (sv)	1988-09-16
NO893702D0 (no)	1989-09-15
DK456989D0 (da)	1989-09-15
EP0368819B1 (en)	1998-01-07
EP0368819A1 (en)	1990-05-16

Legal Events

Date	Code	Title	Description
1994-06-15	GB	Transfer or assigment of application	Owner name: VITEC AKTIEBOLAG
2004-08-31	FG	Patent granted	Owner name: VITEC AKTIEBOLAG

Publication	Publication Date	Title
Sanchez et al.	1989	Recombinant system for overexpression of cholera toxin B subunit in Vibrio cholerae as a basis for vaccine development.
JP5566684B2 (ja)	2014-08-06	Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン
Vodkin et al.	1988	A heat shock operon in Coxiella burnetti produces a major antigen homologous to a protein in both mycobacteria and Escherichia coli
Sanchez et al.	1988	Genetic fusion of a non‐toxic heat‐stable enterotoxin‐related decapeptide antigen to cholera toxin B‐subunit
Dertzbaugh et al.	1990	Cholera toxin B-subunit gene fusion: structural and functional analysis of the chimeric protein
US7238345B1 (en)	2007-07-03	Recombinant microorganism expressing meningococcal class 1 outer membrane protein
US20050244425A1 (en)	2005-11-03	Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability
JP2002541808A (ja)	2002-12-10	ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
EP0746621A1 (en)	1996-12-11	Expression of proteins on bacterial surface
EP0584167A1 (en)	1994-03-02	Recombinant dna coding for signal peptide, selective interacting polypeptide and membrane anchoring sequence
Sanchez et al.	1990	Recombinant cholera toxin B subunit and gene fusion proteins for oral vaccination
US5268276A (en)	1993-12-07	Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
NZ220027A (en)	1990-04-26	Antigens or haptens coupled to escherichia coli outer membrane proteins for enhancement of immune response
FI104496B (fi)	2000-02-15	Yliekspressiojärjestelmät kolera B-alayksikön ekspressiota varten vieraiden promoottoreiden ja johtopeptidien avulla
Haeuw et al.	1998	The recombinant Klebsiella pneumoniae outer membrane protein OmpA has carrier properties for conjugated antigenic peptides
CA2219943C (en)	2010-10-12	Hybrid molecules between heat-labile enterotoxin and cholera toxin b subunits
JPH05503420A (ja)	1993-06-10	キメラタンパク質
US5834246A (en)	1998-11-10	Recombinant systems for expression of cholera B-subunit with the aid of foreign promoters and/or leader peptides
US20030165526A1 (en)	2003-09-04	Vaccines and agents for inducing immunity against rickettsial diseases, and associated preventative therapy
US6043057A (en)	2000-03-28	Recombinant systems for expression of the cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
US6015889A (en)	2000-01-18	Protein rib, a cell surface protein that confers immunity to many strains of the group B streptococcus: process for purification of the protein, reagent kit and pharmaceutical composition
Bäckström et al.	1995	Characterization of an internal permissive site in the cholera toxin B-subunit and insertion of epitopes from human immunodeficiency virus-1, hepatitis B virus and enterotoxigenic Escherichia coli
JP3135060B2 (ja)	2001-02-13	ヘモフィルスインフルエンザｂ型菌の外皮膜タンパク質Ｐ２の部分断片を用いた接合体
GB2356632A (en)	2001-05-30	OspA lipoproteins
US5976839A (en)	1999-11-02	Immunopotentiation through covalent linkage between immunogen and immunopotentiating molecules